Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Acetyl-l-tyrosine
2. N-acetyltyrosine
3. N-acetyltyrosine, (d)-isomer
4. N-acetyltyrosine, (dl)-isomer
1. 537-55-3
2. Ac-tyr-oh
3. N-acetyl-tyrosine
4. Acetyl Tyrosine
5. Acetyl-l-tyrosine
6. L-tyrosine, N-acetyl-
7. L-n-acetyltyrosine
8. N-acetyltyrosin
9. Melanowhite-a
10. (2s)-2-acetamido-3-(4-hydroxyphenyl)propanoic Acid
11. Tyrosine, N-acetyl-
12. Chembl65543
13. Da8g610zo5
14. Chebi:21563
15. (s)-2-acetamido-3-(4-hydroxyphenyl)propanoic Acid
16. (2s)-2-acetylamino-3-(4-hydroxyphenyl)propanoic Acid
17. N-acetyltyrosine (n-acetyl-l-tyrosine)
18. Ncgc00159393-02
19. Ncgc00159393-03
20. Dsstox_cid_26045
21. Dsstox_rid_81305
22. Dsstox_gsid_46045
23. (+)-(2s)-2-(acetylamino)-3-(4-hydroxyphenyl)propanoic Acid
24. Mfcd00037190
25. Cas-537-55-3
26. N-aceyl-l-tyrosine
27. L-tyrosine, Acetyl-
28. Tyrosine, N-acetyl-, L-
29. N-acetyltyrosine (van)
30. Unii-da8g610zo5
31. Nsc-10853
32. N-acetyl Tyrosine
33. Einecs 208-671-3
34. Nsc 10853
35. L-n-acetyl-tyrosine
36. Tanogen Hb
37. Tyr-excel
38. Acetyl L-tyrosine
39. N-acetyl-l-tyrosine,(s)
40. L-tyrosine, N-acetyl
41. Schembl321220
42. Acetyl Tyrosine [inci]
43. (2s)-2-(acetylamino)-3-(4-hydroxyphenyl)propanoic Acid
44. Dtxsid7046045
45. N-acetyltyrosin [who-dd]
46. Zinc156395
47. Tox21_111630
48. Ac7826
49. Bdbm50043802
50. S6316
51. Akos010396311
52. Akos015841008
53. N-acetyl-l-tyrosine [usp-rs]
54. N-acetyl-l-tyrosine, >99% (tlc)
55. Tox21_111630_1
56. Am82306
57. Cs-w013098
58. Db11102
59. Hy-w012382
60. N-acetyltyrosine [ep Monograph]
61. Ac-13390
62. Ds-15166
63. (2s)-2-acetylamino-3-(4-hydroxyphenyl)propanoate
64. (s)-2-acetamido-3-(4-hydroxyphenyl)propanoicacid
65. 537a553
66. A829762
67. J-300276
68. N-acetyl-l-tyrosine 100 Microg/ml In Acetonitrile
69. Q-201443
70. A53ee723-a216-4295-8abe-c8c9ee26bbfc
71. Q27109405
72. (s)-2-acetylamino-3-(4-hydroxy-phenyl)-propionic Acid
73. 2-(s)-acetylamino-3-(4-hydroxy-phenyl)-propionic Acid
74. N-acetyltyrosine, European Pharmacopoeia (ep) Reference Standard
75. N-acetyl-l-tyrosine, United States Pharmacopeia (usp) Reference Standard
76. N-acetyl-l-tyrosine, Pharmaceutical Secondary Standard; Certified Reference Material
77. 3nf
78. N-acetyl-l-tyrosine, Pharmagrade, Ajinomoto, Ep, Manufactured Under Appropriate Gmp Controls For Pharma Or Biopharmaceutical Production, Suitable For Cell Culture
Molecular Weight | 223.22 g/mol |
---|---|
Molecular Formula | C11H13NO4 |
XLogP3 | -0.2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 4 |
Exact Mass | 223.08445790 g/mol |
Monoisotopic Mass | 223.08445790 g/mol |
Topological Polar Surface Area | 86.6 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 259 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
N-acetyltyrosine is indicated, in combination with several other amino acids and dextrose, as a peripherally administered source of nitrogen for nutritional support in patients with adequate stores of body fat in whom, for short periods, oral administration cannot be tolerated, is undesirable, or inadequate. It is also indicated, with other amino acids, 5-10% dextrose, and fat emulsion, for parenteral nutrition to preserve protein and reduce catabolism in stress conditions where oral administration is inadequate. When administered with other amino acids and concentrated dextrose, it is indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where the alimentary tract by the oral, gastrostomy, or jejestomy routes cannot or should not be used or in patients in which gastrointestinal absorption of protein is impaired, metabolic requirements for protein are substantially increased, or morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdown
FDA Label
N-acetyltyrosine is used as a high solubility precursor to [DB00135] used due to [DB00135]'s poor solubility. It is deacetylated to form [DB00135].
Route of Elimination
N-acetyltyrosine is eliminated in the urine. The extent of urinary elimination versus utilization in the tissues appears to be related to the rapidity of infusion. When infused slowly in standard doses as in the clinical setting, about 35% is excreted unchanged in the urine. When larger doses are infused rapidly, much higher amounts are excreted reaching values up to 56%. In rat studies it was found that of the drug eliminated in the urine about 74% is present as unchanged N-acetyltyrosine and 23% is present as tyrosine.
Used as a source of [DB00135]. See [DB00135] for more information on its role and pharmacology.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A N-Acetyl-L-Tyrosine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of N-Acetyl-L-Tyrosine, including repackagers and relabelers. The FDA regulates N-Acetyl-L-Tyrosine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. N-Acetyl-L-Tyrosine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of N-Acetyl-L-Tyrosine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A N-Acetyl-L-Tyrosine supplier is an individual or a company that provides N-Acetyl-L-Tyrosine active pharmaceutical ingredient (API) or N-Acetyl-L-Tyrosine finished formulations upon request. The N-Acetyl-L-Tyrosine suppliers may include N-Acetyl-L-Tyrosine API manufacturers, exporters, distributors and traders.
click here to find a list of N-Acetyl-L-Tyrosine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A N-Acetyl-L-Tyrosine DMF (Drug Master File) is a document detailing the whole manufacturing process of N-Acetyl-L-Tyrosine active pharmaceutical ingredient (API) in detail. Different forms of N-Acetyl-L-Tyrosine DMFs exist exist since differing nations have different regulations, such as N-Acetyl-L-Tyrosine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A N-Acetyl-L-Tyrosine DMF submitted to regulatory agencies in the US is known as a USDMF. N-Acetyl-L-Tyrosine USDMF includes data on N-Acetyl-L-Tyrosine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The N-Acetyl-L-Tyrosine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of N-Acetyl-L-Tyrosine suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing N-Acetyl-L-Tyrosine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for N-Acetyl-L-Tyrosine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture N-Acetyl-L-Tyrosine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain N-Acetyl-L-Tyrosine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a N-Acetyl-L-Tyrosine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of N-Acetyl-L-Tyrosine suppliers with NDC on PharmaCompass.
N-Acetyl-L-Tyrosine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of N-Acetyl-L-Tyrosine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right N-Acetyl-L-Tyrosine GMP manufacturer or N-Acetyl-L-Tyrosine GMP API supplier for your needs.
A N-Acetyl-L-Tyrosine CoA (Certificate of Analysis) is a formal document that attests to N-Acetyl-L-Tyrosine's compliance with N-Acetyl-L-Tyrosine specifications and serves as a tool for batch-level quality control.
N-Acetyl-L-Tyrosine CoA mostly includes findings from lab analyses of a specific batch. For each N-Acetyl-L-Tyrosine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
N-Acetyl-L-Tyrosine may be tested according to a variety of international standards, such as European Pharmacopoeia (N-Acetyl-L-Tyrosine EP), N-Acetyl-L-Tyrosine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (N-Acetyl-L-Tyrosine USP).
LOOKING FOR A SUPPLIER?